Latest 5-alpha reductase Stories
Men receiving testosterone supplementation who also received a drug (dutasteride) commonly used to treat an enlarged prostate gland and which blocks the conversion of testosterone to its potent metabolite DHT did not experience a significant difference in changes in certain outcomes such as muscle mass, muscle strength, or sexual function compared to men who did not receive dutasteride.
When compared with placebo and other drugs, long-term use of finasteride improves urinary tract symptoms associated with benign prostatic hyperplasia, and reduces disease progression.
-- Data Presented at American Urological Association Annual Meeting -- SEATTLE and CHICAGO, April 28 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets TRPM8 (a transmembrane cation channel protein), to treat benign prostatic hyperplasia (BPH).
Healthy men screened regularly for prostate cancer who show no symptoms should talk with doctors about a drug, new U.S.
Use of a class of medications for treating an enlarged prostate is not associated with an increased hip fracture risk, U.S. researchers said. Benign prostatic hyperplasia, or an enlarged prostate, is a common condition that affects some 8 million U.S.